Previous 10 | Next 10 |
Unsurprisingly, investors appear to be locking in profits after the extended rally in COVID-19 vaccine names considering the breathtaking rise in many of the players. More news on: Pfizer Inc., AstraZeneca PLC, Sanofi, Healthcare stocks news, Stocks on the move, Read more ...
FinancialBuzz.com News Commentary New York, NY (8/12/2020) – As of this week, over 5 million people have been confirmed to be infected with the virus in the United States alone, with more than 20 million globally. As a result, health care systems are overwhelmed and the effective delive...
The New York Times reports that Russia's President Vladimir Putin is claiming victory in the global race to a COVID-19 vaccine with today's announcement that its home-grown offering, based on two adenovirus strains akin to Oxford University and AstraZeneca's ( AZN +0.2% ) candidate ChA...
"As far as I know, a vaccine against a new coronavirus infection has been registered this morning, for the first time in the world," Russian President Vladimir Putin declared, according to RIA Novosti . More news on: Pfizer Inc., BioNTech SE, Novavax, Inc., Healthcare stocks news, Top s...
Penny Stock News Has These 4 Names Trending This Week When it comes to penny stocks , the news is easily one of the top catalysts to look for. Key developments are important for investors to pay attention to, obviously. Aside from the initial headlines, you’ll also want to actually rea...
Seres Therapeutics (NASDAQ: MCRB ) +266% on success of lead drug in C. diff study. More news on: Seres Therapeutics, Inc., Trevena, Inc., Hoth Therapeutics, Inc., Stocks on the move, , Read more ...
IBio (NYSEMKT: IBIO ) announces results from ten preclinical study arms assessing a line-up of adjuvants with IBIO-201, its proprietary lichenase carrier molecule (branded as LickM) fused to a coronavirus subunit protein, one of its two COVID-19 vaccine candidates (IBIO-200). More news...
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology corporation and biologics contract manufacturing organization, today provided an update on one of its proprietary vaccine candidates being d...
iBio Pharma (NYSEMKT: IBIO) and Vaxart (NASDAQ: VXRT) rank as two of the biggest winners so far this year among small-cap biotechs with coronavirus programs. Shares of iBio have skyrocketed more than 1,600% year to date, while Vaxart stock is up close to 2,500%. Which of these coronavir...
In a note, SVB Leerink warns that the current $115B aggregate valuation for COVID-19 vaccine developers is, unsurprisingly, overly optimistic. More news on: BioNTech SE, Moderna, Inc., AstraZeneca PLC, Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...